nect Biopharma (US:CNTB) Jin Rong Jie·2025-12-15 15:15Group 1 - The core viewpoint of the article highlights the financial struggles of Conade Biopharma (CNTB), with a significant decline in revenue and net profit [1] - As of December 15, CNTB's stock opened at $2.5 per share, reflecting a 2.88% increase, with a total market capitalization of $140 million [1] - Financial data indicates that by September 30, 2025, CNTB's total revenue is projected to be $64,000, representing a 99.75% year-over-year decrease [1] Group 2 - The company reported a net loss of $40.37 million, which is a staggering 500.58% decrease compared to the previous year [1] - Conade Biopharma is characterized as a biopharmaceutical company in the clinical stage, focusing on developing innovative therapies through its proprietary T-cell function modulation platform [1] - The company's mission is to improve the quality of life for patients suffering from inflammatory immune diseases [1]